Acupuncture and Escitalopram for Treating Major Depression Clinical Study
Not Applicable
Not yet recruiting
- Conditions
- Depressive Disorder, Major
- Registration Number
- NCT05901571
- Lead Sponsor
- Shanghai 7th People's Hospital
- Brief Summary
We will be able to investigate in a sample of patients free of antidepressants whether acupuncture is more effective than placebo.
- Detailed Description
This is a multicenter, randomized, controlled, 2 by 2 factorial clinical trial for Major depression.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 216
Inclusion Criteria
- Between 18 and 75 years of age with no gender-based restriction.
- Fulfilling the diagnostic criteria of DSM-5 for major depressive disorder.
- A Hamilton Rating Scale for Depression (HDRS-17) score ≥ 17
- Ability to read and understand Mandarin Chinese, at least nine years of education, and willingness to adhere to the study protocol.
- The absence of acupuncture treatment within at least 1 year.
- Willingness to participate in the trial and provide written informed consent for the clinical trial.
Exclusion Criteria
- Lifetime or current neuropsychiatric conditions, such as bipolar disorder, schizophrenia, substance dependence or abuse, dementia, brain injury, epilepsy and so forth.
- High suicide risk or presenting with suicidal ideation (a score of more than 2 points on the Suicide question of the HDRS-17) at the time of entry.
- Medicated with antidepressant at the start of the trial or history of treatment failure to escitalopram.
- Pregnancy or breastfeeding.
- Subjects who have acute inflammation at the planned acupuncture site on the body or any other contraindication to acupuncture.
- Candidates afraid of needles in general and reluctant to receive acupuncture in particular
- Known or suspected clinically unstable systemic medical disorder (including cancer, organ failure, or severe diseases of the cardiovascular, severe hepatic or renal insufficiency).
- Previous participation in other acupuncture trials.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HDRS-17 score from baseline to 10 weeks the change in the HDRS-17 score
- Secondary Outcome Measures
Name Time Method The CGI(Clinical Global Impression) from baseline to 10 weeks the change in the CGI
Beck depression inventory score from baseline to 10 weeks the change in the Beck depression inventory score
The GAD-7(General Anxiety Disorder) from baseline to 10 weeks the change in the GAD-7
The Mini-Mental State Examination (MMSE) from baseline to 10 weeks the change in the MMSE
Trial Locations
- Locations (3)
Jianhua Chen
🇨🇳Shanghai, Shanghai, China
Zhenxiang Han
🇨🇳Shanghai, Shanghai, China
Zouqing Huang
🇨🇳Shanghai, Shanghai, China
Jianhua Chen🇨🇳Shanghai, Shanghai, ChinaJianhua Chen, DrContact+86 216487250